Application No.: 09/869,208 3 Docket No.: 07238/000J504-US0

THIS LISTING OF CLAIMS WILL REPLACE ALL PRIOR VERSIONS, AND LISTINGS, OF CLAIMS IN THE APPLICATION:

LISTING OF CLAIMS:

- 1. Cancel
- 2. (Currently amended) A phagocyte-recognizing agent recognizing an antigen expressed on granulocyte-macrophage colony stimulating factor (GM-CSF)-primed granulocytes that is recognized by at least one bacteriophage isolated from the strains having accession numbers CBS 101481 and 101482 or is recognized by an ScFv fragment having sequences expressed on said bacteriophage, said agent also having the property of competing with at least one of said bacteriophage in binding to said primed granulocytes.
- 3. (Previously presented) The phagocyte-recognizing agent according to claim 2, wherein it possesses a group having a phagocyte-deactivating activity.
- 4. Cancel
- 5. (Currently Amended and Withdrawn) Method of detecting a preactivated phagocyte, wherein a phagocyte-recognizing agent eapable of recognizing the antigen expressed on granulocyte-macrophage colony stimulating factor (GM-CSF)-primed granulocytes that is recognized by at least one bacteriophage as can be isolated from the strains having accession numbers CBS 101481 and 101482 or is recognized by an ScFv fragment having sequences expressed on said bacteriophage, and said agent also having the property of competing with at least one of said bacteriophage in binding to a granulocyte primed with GM-CSF, is

contacted with a phagocyte, and a complex formed between the phagocyte-recognizing agent and the phagocyte is detected.

- 6. (Cancel)
- 7. (Withdrawn) Method according to claim 6, wherein the agent is a bacteriophage.
- 8. (Withdrawn) Method according to claim 6, wherein the agent is a fluorescent agent.
- 9. (Withdrawn) Method according to claim 8, wherein the agent comprises
 Green or Blue Fluorescent Protein.
- 10. (Withdrawn) Method according to claim 8, wherein detection is performed by means of a Fluorescence-Activated Cell Sorter (FACS).
- 11. (Withdrawn) Method according to claim 5, wherein the detection is performed by means of an ELISA.
- 12. (Withdrawn) Method according to claim 5, wherein the phagocyte is derived from a person of which it is thought that it suffers from an affection chosen from the group consisting of i) organ-bound inflammatory diseases; ii) septic shock; iii) allergies; and iv) auto-immune diseases; or of a person having undergone a transplantation.
- 13. (Withdrawn) Method according to claim 12, wherein for detection blood from a person is lysed using an isotonic, cold NH₄Cl-solution yielding a phagocyte-containing solution.
- 14. (Cancel)

Application No.: 09/869,208

15. (Currently Amended) The phagocyte-recognizing agent of claim [[14]] 2, which comprises an antigen-binding part of an antibody.

5

- 16. (Previously Presented) The phagocyte-recognizing agent of claim 15, which is a monoclonal antibody.
- 17. (Currently Amended) The phagocyte-recognizing agent of claim 2, which comprises the antigen-specific antigen-recognizing sequence of a bacteriophage from a strain selected from the strains having accession numbers CBS101481 and CBS101482.
- 18. (Currently Amended) A phagocyte-binding agent eapable having the property of competitively inhibiting the binding of a bacteriophage isolated from a strain selected from CBS 101481 and CBS 101482 to a preactivated phagocyte.
- 19. (Currently Amended) The phagocyte-binding agent of claim 18, wherein the phaghocyte phagocyte is a GM-CSF primed leukocyte.
- 20. (Currently Amended) The phagocyte-binding agent of claim 18, wherein the phagocyte-binding agent comprises an antigen-binding part fragment of an antibody.
- 21. (Previously Presented) The phagocyte-binding agent of claim 20, which is a monoclonal antibody.
- 22. (Previously Presented) The pharmaceutical composition of claim 4, wherein the phagocyte-recognizing agent comprises an antigen-binding part of an antibody capable of competing with the bacteriophage in binding to a GM-CSF primed granulocyte.
- 23. (New) The phagocyte-recognizing agent of claim 2, wherein the agent is an ScFv fragment with the antigen-recognizing sequence of

Docket No.: 07238/000J504-US0

Application No.: 09/869,208

bacteriophage isolated from the strain having accession number CBS 101481.

24. (New) The phagocyte-recognizing agent of claim 2, wherein the agent is a humanized antibody with the antigen-recognizing sequence of bacteriophage isolated from the strain having accession number CBS 101481.